For the quarter ending 2025-12-31, INBS had -$919,734 decrease in cash & cash equivalents over the period. -$1,635,747 in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Impairment of long-lived assets | - | 261,780 | 220,062 |
| Provision for credit losses | - | 73 | 546 |
| Net loss | -2,686,613 | -2,994,992 | -10,604,886 |
| Depreciation and amortization | 327,367 | 257,907 | 970,117 |
| Impairment of long-lived assets | 243,456 | 45,471 | 243,632 |
| Stock-based compensation | 61,575 | 12,000 | 238,045 |
| Non-cash adjustment on r&d expenditure claims | -127,108 | - | 137,696 |
| Non-cash other operating activities | 115,509 | -147,842 | -113,645 |
| Accounts receivable | -261,166 | 123,209 | 164,910 |
| Non-cash loss on foreign currency translation, net | - | - | 0 |
| Inventories | -37,931 | -7,038 | -142,322 |
| Research and development tax incentive receivable | -418,890 | 189,654 | 209,076 |
| Other current assets | -8,049 | -338,794 | 329,404 |
| Provision for inventory obsolescence | - | - | 0 |
| Accounts payable and accrued expenses | 45,450 | -567,109 | 2,577,151 |
| Grant receivable / deferred grant income | - | - | 2,486,668 |
| Long-term employee benefit liabilities | 6,885 | 15,120 | 21,306 |
| Fair value gain on revaluation of holdback series c preferred stock | - | - | 0 |
| Operating lease liabilities | -41,417 | -57,886 | -271,499 |
| Net cash used in operating activities | -1,567,515 | -2,846,825 | -9,677,313 |
| Proceeds from sale of assets held for sale | 40,158 | - | - |
| Purchase of property and equipment | 68,232 | 70,401 | 231,838 |
| Net cash used in investing activities | -28,074 | -70,401 | -231,838 |
| Proceeds from exercise of warrants, net of issuance costs | - | - | 7,939 |
| Proceeds from private placement, net of issuance costs | - | - | 0 |
| Proceeds from issuance of common stock, net of issuance costs | 674,651 | 224,534 | 4,589,866 |
| Proceeds from issuance of common stock for warrants exercised, net of issuance costs | 0 | 3,333,631 | - |
| Net cash provided by financing activities | 674,651 | 3,558,165 | 4,597,805 |
| Effect of foreign exchange rates on cash and cash equivalents | 1,204 | -743 | 27,157 |
| Net decrease in cash and cash equivalents | -919,734 | 640,196 | -5,284,189 |
| Cash and cash equivalents at beginning of period | 1,660,105 | 1,019,909 | - |
| Cash and cash equivalents at end of period | 740,371 | 1,660,105 | - |
INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)